Ganglion cells help set the human body clock

Article

Cells at the back of the eyes of profoundly blind people monitor light levels and use them to set the body's clock to either day or night.

Cells at the back of the eyes of profoundly blind people monitor light levels and use them to set the body's clock to either day or night, according to a report published in the December issue of Current Biology.

Russell Foster from the Nuffield Laboratory of Ophthalmology, University of Oxford, UK and colleagues from other UK and US centres conducted an experiment on two blind people who lack the rods and cones needed for normal vision.

For 6.5 hours, the researchers shone light into the eyes of a 56-year old blind man and an 87-year old blind woman. When they used the blue light at night-time, they were able to delay the body clock cycle by 1.2 hours, proving that the ganglion cells were registering light. At the same time, blood levels of the sleep hormone melatonin fell by 60% and the patients' alertness sharpened and brain activity increased, demonstrating that the body clocks had been "fooled" into thinking it was daytime.

The researchers believe that the results of this study explain why blind people, who have had their eyes removed for cosmetic or health reasons, can suffer significant sleep disruption.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.